Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1
RNA-seq (gene expression) · human · 77 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- CholangiocarcinomaThis series is part of our curated briefing on it.
- Samples
- 77 samples: 17 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma modelsScience translational medicine · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE262166_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1090498 and SRA study SRP496658. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 4 samples read as cases, 19 as controls.
How we read this: 17 replicated groups read from 77 sample titles; they account for 65 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8155752 PDM17_ctl1 PDM17_ctl
- GSM8155753 PDM17_ctl2 PDM17_ctl
- GSM8155754 PDM17_ctl3 PDM17_ctl
- GSM8155755 PDM17_H3L31 PDM17_H3L
- GSM8155756 PDM17_H3L32 PDM17_H3L
- GSM8155757 PDM17_H3L33 PDM17_H3L
- GSM8155758 506
- GSM8155759 509
- GSM8155760 510
- GSM8155761 516
- GSM8155762 517
- GSM8155763 508
- GSM8155764 512
- GSM8155765 514
- GSM8155766 515
- GSM8155767 521
- GSM8155768 CCA_CTRL_Tum1_plate151 CCA_CTRL_Tum1_plate
- GSM8155769 CCA_CTRL_Tum1_plate152 CCA_CTRL_Tum1_plate
- GSM8155770 CCA_CTRL_Tum1_plate153 CCA_CTRL_Tum1_plate
- GSM8155771 CCA_CTRL_Tum1_plate154 CCA_CTRL_Tum1_plate
- GSM8155772 CCA_Treated_Tum2_plate162 CCA_Treated_Tum2_plate
- GSM8155773 CCA_Treated_Tum2_plate163 CCA_Treated_Tum2_plate
- GSM8155774 CCA_Treated_Tum2_plate164 CCA_Treated_Tum2_plate
- GSM8155775 CCA_Treated_Tum2_plate165 CCA_Treated_Tum2_plate
- GSM8158989 R5889
- GSM8158990 R5909
- GSM9014046 CDX, HuCC-A1, rep1 CDX, HuCC-A1,
- GSM9014047 CDX, HuCC-A1, rep2 CDX, HuCC-A1,
- GSM9014048 CDX, HuCC-A1, rep3 CDX, HuCC-A1,
- GSM9014049 CDX, HuCC-A1, rep4 CDX, HuCC-A1,
- GSM9014050 CDX, HuCC-A1, rep5 CDX, HuCC-A1,
- GSM9014051 CDX, EGI-1, rep1 CDX, EGI-1,
- GSM9014052 CDX, EGI-1, rep2 CDX, EGI-1,
- GSM9014053 CDX, EGI-1, rep3 CDX, EGI-1,
- GSM9014054 CDX, EGI-1, rep4 CDX, EGI-1,
- GSM9014055 CDX, EGI-1, rep5 CDX, EGI-1,
- GSM9014056 CDX, HuCC-T1, rep1 CDX, HuCC-T1,
- GSM9014057 CDX, HuCC-T1, rep2 CDX, HuCC-T1,
- GSM9014058 CDX, HuCC-T1, rep3 CDX, HuCC-T1,
- GSM9014059 CDX, HuCC-T1, rep4 CDX, HuCC-T1,
+ 37 more — browse all 77 samples with per-sample file links →
- GSE273905 Targeting Cancer Associated Fibroblasts/Tumor Cells Cross-Talk Inhibits Intrahepatic Cholangiocarcinoma Progression 9 samples same disease briefing · shares cholangiocarcinoma, targeting
- GSE33327 Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes 283 samples same disease briefing · shares cholangiocarcinoma
- GSE26566 Molecular classification of human cholangiocarcinoma 169 samples same disease briefing · shares cholangiocarcinoma
- GSE89749 Integrative genomic and epigenetic analysis in cholangiocarcinoma 120 samples same disease briefing · shares cholangiocarcinoma
- GSE231854 The heterogeneity analysis of hepatocellular carcinoma and combined hepatocellular cholangiocarcinoma 81 samples same disease briefing · shares cholangiocarcinoma
- GSE317889 Combined DNA and RNA profiling refines prognostic stratification independent of therapeutic actionability in cholangiocarcinoma 62 samples same disease briefing · shares cholangiocarcinoma
- GSE274024 NOX4/NOX1 dual inhibition in cholangiocarcinoma as an effective approach to target TGF-beta protumorigenic actions in cancer associated fibroblasts 45 samples same disease briefing · shares cholangiocarcinoma
- GSE318391 Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma 39 samples same disease briefing · shares cholangiocarcinoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.